A trial of weekly low-dose methotrexate )LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome

Investigate whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages.

September 25, 2015

  • Clinical Trial Information

    Trial Contact: Peisner, Pamela

    Trial Phone: 321.843.1037

  • Age Group: Adult

    Phase: Drug: Phase III

    Principal Investigator: Sundeep Mediratta, MD

    Sub Investigators: Terrence M Gross MD;

    IRB No: 13.147.09

    Secondary Protocol No: Version 1.7

    Applicable Disease Sites: Diabetes, CAD, MI, Metabolic Syndrome